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Interest is rapidly rising in the Surface‐Activated Chemical Ionization/Electrospray Ionization (SACI‐ESI) technology due to its application for highly sensitive detection of low molecular weight compounds, in particular when applied for biomarker discovery.[1](#rcm7270-bib-0001){ref-type="ref"} SACI/ESI makes it possible to efficiently detect potential disease‐related biomarker candidate metabolite signals[1](#rcm7270-bib-0001){ref-type="ref"}, [2](#rcm7270-bib-0002){ref-type="ref"}, [3](#rcm7270-bib-0003){ref-type="ref"} and represents a new frontier in the medical diagnostic field, providing relevant information beyond conventional analysis of blood and urine. Among the different approaches developed for mass spectrometry (MS) biomarker discovery over the last few years,[4](#rcm7270-bib-0004){ref-type="ref"}, [5](#rcm7270-bib-0005){ref-type="ref"}, [6](#rcm7270-bib-0006){ref-type="ref"}, [7](#rcm7270-bib-0007){ref-type="ref"}, [8](#rcm7270-bib-0008){ref-type="ref"}, [9](#rcm7270-bib-0009){ref-type="ref"} SACI/ESI has been shown to be more sensitive and accurate with respect to classic mass spectrometric technologies based on electrospray ionization (ESI) alone and Atmospheric Pressure Chemical Ionization.[1](#rcm7270-bib-0001){ref-type="ref"}, [2](#rcm7270-bib-0002){ref-type="ref"}, [3](#rcm7270-bib-0003){ref-type="ref"} A strong reduction in matrix effect together with improved quantification performance was obtained with SACI when matched with ESI.[1](#rcm7270-bib-0001){ref-type="ref"}, [2](#rcm7270-bib-0002){ref-type="ref"}, [3](#rcm7270-bib-0003){ref-type="ref"}

Here we developed a bioinformatic tool, termed SANIST, that combines single ion monitoring LC/SACI/ESI‐MS data acquisition of the *m/z* (Thompson units) signal related to potential biomarker candidates[1](#rcm7270-bib-0001){ref-type="ref"}, [2](#rcm7270-bib-0002){ref-type="ref"}, [3](#rcm7270-bib-0003){ref-type="ref"} with a sample classification based on an innovative and modified Baysian mathematical model. This novel algorithm is based on the comparison of a selected biomarker fingerprint with those stored in a database using an improved Bayesian mathematical model. Prostate cancer (PCa) was used as the disease model in order to test the SANIST platform. PCa is a leading cause of mortality and morbidity in males worldwide. New effective diagnostic approaches are urgently needed as prostate‐specific antigen (PSA), the best‐known prostate cancer biomarker candidate, is prostate but not cancer specific, thus resulting in false positives.[10](#rcm7270-bib-0010){ref-type="ref"}, [11](#rcm7270-bib-0011){ref-type="ref"}, [12](#rcm7270-bib-0012){ref-type="ref"} Sarcosine, recently identified in a metabolomic study,[13](#rcm7270-bib-0013){ref-type="ref"} has come under scrutiny as a PCa marker.[14](#rcm7270-bib-0014){ref-type="ref"}, [15](#rcm7270-bib-0015){ref-type="ref"} We first performed an initial SANIST biomarker discovery on a training set of sera from 15 patients with histologically confirmed prostate cancer and 13 subjects whose biopsies showed benign prostate hyperplasia (BPH). The SANIST approach was used to validate the potential differentially expressed biomarker candidates on a second training set. In particular, three carnitines (decanoyl‐l‐, octanoyl‐l‐ and 5‐*cis*‐tetradecenoyl carnitine) were detected at lower levels in individuals whose biopsies were positive for prostate cancer. Carnitine is essential for lipid energy metabolism within the mitochondria and in particular fatty acid metabolism.[16](#rcm7270-bib-0016){ref-type="ref"} Differentially expressed plasma carnitine levels have been found in cancer patients, often ascribed to malnutrition.[17](#rcm7270-bib-0017){ref-type="ref"} Clinically, L‐carnitine and its derivatives (acetyl‐L‐carnitine; propionyl‐L‐carnitine) are under study to combat wasting and chemotherapy‐induced peripheral neuropathy.[18](#rcm7270-bib-0018){ref-type="ref"}, [19](#rcm7270-bib-0019){ref-type="ref"}, [20](#rcm7270-bib-0020){ref-type="ref"} Carnitine supplementation in several experimental models has been shown to slow down tumor growth.[21](#rcm7270-bib-0021){ref-type="ref"}, [22](#rcm7270-bib-0022){ref-type="ref"}, [23](#rcm7270-bib-0023){ref-type="ref"}, [24](#rcm7270-bib-0024){ref-type="ref"}, [25](#rcm7270-bib-0025){ref-type="ref"} Molecular mechanisms suggested include increased generation of reactive oxygen species (ROS), induction of apoptosis and histone deacetylase (HDAC) inhibition. The biomarker panel identified in the training set was then applied to a second set of sera from 15 prostate cancer positive and 15 BPH subjects, showing a high sensitivity and specificity in separation of individuals with prostate cancer from those with benign conditions.

Experimental {#rcm7270-sec-0006}
============

Chemicals {#rcm7270-sec-0007}
---------

Methanol (CH~3~OH), acetonitrile (CH~3~CN), bi‐distilled water, acetone (C~3~H~6~O), reserpine and formic acid (HCOOH) were purchased from Sigma Aldrich (Milan, Italy). The Ultramark mix was bought from ThermoFisher (San Jose, CA, USA).

Patient selection, sample preparation and collection {#rcm7270-sec-0008}
----------------------------------------------------

Patients were male individuals, aged 50 or more, undergoing a prostate biopsy for PCa diagnosis at the Urology Unit of the MultiMedica Castellanza. Controls, here referred to as benign prostate hyperplasia (BPH), were selected among individuals that had been diagnosed as prostate cancer negative at the time of their biopsy. Patients affected by autoimmune diseases, allergies and other immune‐mediated conditions were excluded. The institutional review board ethics committee approved the study. Blood samples were collected in siliconized tubes, left to coagulate for 30 min and then centrifuged for 30 min at 3000 rpm at 4°C to minimize variability during sample collection.[26](#rcm7270-bib-0026){ref-type="ref"} Sera obtained were collected in 1.8‐mL cryotube vials (Thermo Fisher Scientific, Rodano, Milan, Italy) and stored at --80°C until the time of analysis. Patients were classified according to clinical parameters, including total and free PSA at the time of sampling, Gleason level to identify the tumor aggressiveness and histological evaluation of the biopsy. Patients were not undergoing any therapy for PCa at the time of sampling.

For LC/MS analysis, 290 μL of serum were spiked with 10 μL of internal standard (reserpine) at known concentration (10 ng/mL) to obtain both a reference for the reproducibility of sample preparation and instrument performance (the stability and performance of commercial instruments are usually checked using this compound). Then 600 μL of CH~3~CN were added to the spiked serum to precipitate proteins, and the sample was centrifuged. A volume of 600 μL of supernatant was collected and spiked with 100 μL of Ultramark polymer solution (10 ng/mL) to check the LC/MS signal stability during the analysis. Sample was dried using a SpeedVac (ThermoFisher, San Jose, CA, USA). H~2~O/CH~3~OH (1:1) solution (100 μL) was used to re‐suspend the analyte sample mixture.[27](#rcm7270-bib-0027){ref-type="ref"}, [28](#rcm7270-bib-0028){ref-type="ref"}

Chromatography {#rcm7270-sec-0009}
--------------

An Ultimate 3000 UPLC (Thermofisher, San Jose, CA, USA) liquid chromatography apparatus was employed to obtain analyte separation before mass spectrometric analysis. A PFP chromatographic column (50 × 2.1 mm, 1.9 µm; Thermofisher, San Jose, CA, USA) was used for separation. The mobile phases were: (A) H~2~O + 0.2% HCOOH and (B) CH~3~OH. A binary gradient was used: 2% of B was maintained for 5 min, in 10 min B% was raised to 30, in a further 20 min B% was brought to 80% and this was maintained for 5 min; 2% of B was reached in 1 min and the column was re‐equilibrated at the starting conditions for 9 min. The chromatographic flow was 0.55 mL/min. The injection volume was 10 μL.

Mass spectrometry {#rcm7270-sec-0010}
-----------------

Instrument analysis was performed using an Orbitrap mass spectrometer (ThermoFisher, San Jose, USA) coupled to a SACI/ESI source (described previously[1](#rcm7270-bib-0001){ref-type="ref"}) and operated in positive ion mode. Because carnitines exist as zwitterions (positive and negative charges within the molecule) in solution, their analysis in positive ESI mode is more sensitive if a small amount of acid (0.2% HCOOH in our case) is added to the spray eluent. Full‐scan spectra were acquired in the wide range of 40--3500 *m/z* for non‐targeted metabolomics analysis to detect all analyte and calibration *m/z* signals. The same *m/z* range was maintained for both discovery and selective biomarker studies in order to standardize the instrument response across the SANIST study mainly in terms of scan velocity. Ion source parameters used were as follows: ESI capillary voltage 1500 V, SACI surface voltage 47 V, drying gas: 2 L/min, nebulizer gas: 80 psi and temperature: 40°C. Tandem mass spectrometry experiments were performed under collision‐induced dissociation (CID) conditions using He as the collision gas on a serum sample. An ion trap was employed to isolate and fragment the precursor ions (isolation windows ±0.3 m/z, collision energy 30% of its maximum value (5 V peak to peak)) and the Orbitrap mass analyzer was used to obtain the fragments high accurate *m/z* ratio (resolution 15,000, *m/z* error \<10 ppm).

Bioinformatics and data analysis {#rcm7270-sec-0011}
--------------------------------

### Discovery {#rcm7270-sec-0012}

The data were converted into the mzXML format[29](#rcm7270-bib-0029){ref-type="ref"} before data elaboration analysis using Bruker Daltonics Data Analysis software. A XCMS algorithm[30](#rcm7270-bib-0030){ref-type="ref"} was employed in conjunction with an R statistical elaboration package,[31](#rcm7270-bib-0031){ref-type="ref"} in order to obtain both *m/z* discriminant *p* values (t test). Compound identifications were obtained on the basis of a Metlin database search[32](#rcm7270-bib-0032){ref-type="ref"} using the high *m/z* accurate ions. Commercial standards were employed to confirm the identification match. We also employed tandem mass (MS/MS) spectra to support compound identification on a serum sample. The analyte identities were confirmed on the basis of the fragmentation pathway and also using different database elaboration tools (Metlin,[32](#rcm7270-bib-0032){ref-type="ref"} mzCloud[33](#rcm7270-bib-0033){ref-type="ref"}).

### Analysis {#rcm7270-sec-0013}

SANIST data analysis was done using software developed with the LabView (National Instruments Corporation, Austin, TX, USA) visual language.[34](#rcm7270-bib-0034){ref-type="ref"} The SANIST tool acquires the selected potential biomarker panel directly from the SACI/ESI‐MS device and automatically compares these with a reference database containing known PCa and BPH subjects. The software directly acquires the extracted ion chromatogram associated with the potential biomarker ion signal detected in the discovery phase and creates an ASCII file containing numeric values.[35](#rcm7270-bib-0035){ref-type="ref"} The data are imported through an IPV4 protocol. The ion peak area is automatically extracted by the software and processed with the novel SANIST mathematical model based on Bayesian data analysis. SANIST data elaboration is based on the calculation of the probability that the detected disease biomarker profile was related to known disease (e.g. prostate cancer), for which the system was instructed by analyzing and inserting biomarker profiles of serum from biopsy positive (PCa) and negative (BPH) subjects. The Bayes\' theorem measures the probability in which an event occurs. Under this interpretation, Bayes\' theorem is the relationship between P(A) (probability that an acquired profile is a prostate cancer patient), P(B) (probability that a \'fingerprint\' biomarker profile is a biopsy negative subject), P(A\|B) and P(B\|A) for any events A and B in the same event space. In our case A and B represent the biomarker chromatographic peak area and their relative ratios. The Bayesian interpretation of probability, or uncertainty, measures confidence that something is true. Under this interpretation, Bayes\' theorem links uncertainty before and after observing evidence. P(A), the prior, is the initial uncertainty in A. P(A\|B), the posterior, is the uncertainty having accounted for evidence B. P(B\|A)/P(B) represents the degree of support B provides for A. The relationship among the probabilistic function is shown in Eqn. [(1)](#rcm7270-disp-0001){ref-type="disp-formula"}: $$P\left( {A\left| B \right.} \right) = \frac{P\left( {B\left| A \right.} \right)P\left( A \right)}{P\left( B \right)}$$

We introduced a new coefficient in Eqn. [(1)](#rcm7270-disp-0001){ref-type="disp-formula"} that gives Eqn. [(2)](#rcm7270-disp-0002){ref-type="disp-formula"}: $$P\left( {A\left| B \right.} \right) = \frac{P\left( {B\left| A \right.} \right)P\left( A \right)}{P\left( B \right)}{*C\left( {\text{mz},,,\text{rt},,,i} \right)}$$

C(mz,rt,i) is a correction factor that, on the basis of the number of uncorrected sample classifications, makes possible to progressively increase the disease classification accuracy. In our case, the samples are correctly classified as prostate cancer biopsy positive or negative with the SANIST tool. To obtain this result at least 10,000 sequential classification steps are needed. The theorem makes it possible to estimate the probability that the observation observed in the serum is correctly classifiable considering the follow experimental observations: accurate *m/z* value and analyte area (counts/s).

Results and Discussion {#rcm7270-sec-0014}
======================

Serum samples were obtained from subjects undergoing a prostate biopsy for PCa diagnosis ([Supplementary Table S1](#rcm7270-supinf-0001){ref-type="supplementary-material"}, see Supporting Information), which represents a typical clinical situation and challenging biomarker *scenario* where the samples must discriminate between PCa positive and patients with other potential prostate conditions. Samples were subjected to LC/MS analysis using water and CH~3~OH gradients, solvents often used in carnitine studies.[27](#rcm7270-bib-0027){ref-type="ref"}, [28](#rcm7270-bib-0028){ref-type="ref"} In order to obtain potential biomarker candidates for a prostate cancer panel to be used for the SANIST approach, the SACI/ESI data were converted into the mzXML standardized format and elaborated using the XCMS software. Typical representative full scan SACI/ESI mass chromatograms of BPH and prostate cancer subjects extracted under base peak conditions are shown in Figs. [1](#rcm7270-fig-0001){ref-type="fig"}(a) and [1](#rcm7270-fig-0001){ref-type="fig"}(b), respectively. As expected, the chromatographic profiles appear to be quite similar but with noticeable differences; therefore, a comparative alignment analysis of all samples was then obtained employing XCMS.[30](#rcm7270-bib-0030){ref-type="ref"} These data were then analyzed using the R bioinformatic statistical environment[31](#rcm7270-bib-0031){ref-type="ref"} allowing a comparison of all the *m/z* values of the chromatographic peak areas between BPH and prostate cancer subjects. In particular, the XCMS/R approach was useful to obtain a simple t‐test or assessing the statistical validity in difference of levels of each *m/z* value (Table [1](#rcm7270-tbl-0001){ref-type="table-wrap"}). The signals at *m/z* values of 316.256, 288.217 and 370.295 acquired in positive ion mode were all significantly differentially expressed (*p* value \<0.001) at lower levels in the prostate cancer subjects (Table [2](#rcm7270-tbl-0002){ref-type="table-wrap"}) using the reserpine and Ultramark spiked in references. The instrument stability among the samples was tested by measuring the exact *m/z* value extraction mass chromatogram peak area variance (10%) of the reserpine internal standard. The sample instrument average analyte area variation was used to check the reproducibility, and was from 73 to 90%.

![Representative full scan (base peak) extracted ion \'SANIST\' mass chromatograms of (a) biopsy negative (BPH) and (b) biopsy positive (PCa) subjects.](RCM-29-1703-g001){#rcm7270-fig-0001}

###### 

Ions that were differentially expressed between serum samples from BPH and positive prostate cancer (PCa positive) subjects in the discovery study and their corresponding metabolites

  *m/z* value    Ion species           Metabolite name          Fold (Patient area/Control area)   *p* value
  ------------- ------------- --------------------------------- ---------------------------------- -----------
  316.256        \[M+H\]^+^         Decanoyl‐L‐carnitine        0.76                               0.0001
  288.217        \[M+H\]^+^         Octanoyl‐L‐carnitine        0.85                               0.0003
  370.295        \[M+H\]^+^    5‐*cis*‐Tetradecenoyl carnitine  0.72                               0.0004

###### 

Classification percent identity score and absolute identity score obtained on the basis of the SANIST platform and the three identified carnitine biomerkers. All prostate cancer patient (PCa positive) profiles are similar to another prostate cancer, while benign prostate hyperplasia (BPH) are closest to other BPH subjects

  Sample    SANIST sample classification   Absolute identity (‰)   Percent identity score (%)
  -------- ------------------------------ ----------------------- ----------------------------
  P1                PCa Positive                    904                        91
  P2                PCa Positive                    911                        92
  P3                PCa Positive                    903                        90
  P4                PCa Positive                    905                        94
  P5                PCa Positive                    912                        92
  P7                PCa Positive                    920                        91
  P8                PCa Positive                    903                        91
  P9                PCa Positive                    907                        92
  P10               PCa Positive                    904                        93
  P14               PCa Positive                    903                        92
  P16               PCa Positive                    906                        92
  P17               PCa Positive                    905                        93
  P18               PCa Positive                    901                        94
  P19               PCa Positive                    902                        93
  P29               PCa Positive                    913                        91
  C21                   BPH                         923                        90
  C23                   BPH                         908                        91
  C24                   BPH                         909                        91
  C29                   BPH                         905                        93
  C31                   BPH                         904                        94
  C32                   BPH                         914                        93
  C33                   BPH                         905                        90
  C34                   BPH                         914                        91
  C35                   BPH                         903                        91
  C36                   BPH                         906                        90
  C38                   BPH                         907                        92
  C39                   BPH                         903                        92
  C40                   BPH                         903                        93

The identity of target analytes was also supported by means of MS/MS analysis and structural studies. Figures [2](#rcm7270-fig-0002){ref-type="fig"}(a), [2](#rcm7270-fig-0002){ref-type="fig"}(b) and [2](#rcm7270-fig-0002){ref-type="fig"}(c) report their MS/MS spectra, obtained by CID. The high accurate fragment *m/z* ratio and the hypothetical structure are reported in Fig. [2](#rcm7270-fig-0002){ref-type="fig"}.

![MS/MS spectra, obtained by collision‐induced dissociation (CID), of (a) decanoyl‐L‐Carnitine, (b) octanoyl‐L‐carnitine, and (c) 5‐*cis*‐tetradecenoyl carnitine.](RCM-29-1703-g002){#rcm7270-fig-0002}

These data suggest that the selected metabolite levels are biologically relevant candidate biomarkers likely generated by possible altered mitochondrial metabolism of prostate cancer subjects and could represent potentially useful markers for diagnosis. Oxidative stress and apoptosis inhibition are indicative of impaired mitochondrial function that is linked to cancer development.[16](#rcm7270-bib-0016){ref-type="ref"} A correlation between mitochondrial dysfunction and differentially expressed carnitine has been previously described in rats in the context of ifosfamide chemotherapy toxicity.[36](#rcm7270-bib-0036){ref-type="ref"} Propionyl‐L‐carnitine and acetyl‐L‐carnitine have shown to be promising in the management of therapy‐induced peripheral neuropathy in PCa patients without affecting therapeutic efficacy,[20](#rcm7270-bib-0020){ref-type="ref"} and androgen deprivation therapy has been shown to significantly decrease numerous carnitines, including octanoylcarnitine and decanoylcarnitine.[37](#rcm7270-bib-0037){ref-type="ref"}

SANIST software was used to acquire the specific *m/z* values from the extracted mass chromatograms of the selected biomarker signatures, in full scan mode, using the high accuracy Orbitrap mass analyzer. After data acquisition, SANIST automatically proceeds to data elaboration using the Bayesian elaboration model developed in house in order to statistically evaluate the classification efficiency of the carnitine metabolite biomarker \'fingerprint\'. A schematic representation of the SANIST platform is shown in Fig. [3](#rcm7270-fig-0003){ref-type="fig"}. Basically, SANIST directly acquires the extracted ion chromatogram (Fig. [3](#rcm7270-fig-0003){ref-type="fig"}(i)) of the selected ions of interest found during the discovery phase, creating an ascii file containing numeric values (*m/z* value, retention time and extracted ion chromatographic peak area). The ion data are elaborated (Fig. [3](#rcm7270-fig-0003){ref-type="fig"}(ii)) by means of the Bayesian mathematical model: analyte *m/z* value, retention time and their peak chromatographic area are compared to those inserted in the SANIST database and classified as negative or (in this case) positive prostate cancer subjects. In particular, Figs. [4](#rcm7270-fig-0004){ref-type="fig"}(a), [4](#rcm7270-fig-0004){ref-type="fig"}(b) and [4](#rcm7270-fig-0004){ref-type="fig"}(c) show the extracted ion chromatogram peaks obtained by monitoring the \[M+H\]^+^ ions at *m/z* 316.256, 288.217 and 370.295. Two scores are provided by the SANIST software: The absolute identity score (expressed in ‰). This value range is between 1 and 1000 where the score 1000 indicate a complete similarity between the vector of the unknown sample profile and the most similar vector in the database.The percent identity score (expressed in %). This coefficient reports the classification specificity of the subject state (e.g. BPH or unhealthy) identified by the best match score. This is calculated on the basis of the match score difference between that of the best database match and the next best match. A higher difference associates with a higher classification specificity percent. As an initial test, the biomarker fingerprint of each subject was compared with those inserted in the database, excluding the identical match to itself. The samples were then characterized as BPH or prostate cancer on the basis of their similarity with the best match. A complete discrimination (100%) was achieved among BPH and prostate cancer patients in this training set with a recognition identity % match between 90 and 94% (Table [2](#rcm7270-tbl-0002){ref-type="table-wrap"}).

![\'SANIST\' bioinformatics platform scheme based on LabView software: (i) extracted ion chromatogram and (ii) total ion current. The evoluted Bayesian comparisons to a developed database makes it possible to statistically evaluate biomarker panel classification efficiency.](RCM-29-1703-g003){#rcm7270-fig-0003}

![Extracted ion chromatogram peaks obtained by monitoring the \[M+H\]^+^ ions at (a) 316.256 *m/z*, (b) 288.217 *m/z*, and (c) 370.295 *m/z*, corresponding to decanoyl‐L‐carnitine, octanoyl‐L‐carnitine and 5‐*cis*‐tetradecenoyl carnitine, respectively.](RCM-29-1703-g004){#rcm7270-fig-0004}

A second test set of 15 patients and 15 BPH subjects (indicated with 01 as a suffix) were then analyzed using the SANIST platform to verify the potential specificity and selectivity of the fingerprint identified using the training set. The signals at *m/z* values of the three represented metabolites (Table [3](#rcm7270-tbl-0003){ref-type="table-wrap"}) in this test set were comparable to those shown in Table [1](#rcm7270-tbl-0001){ref-type="table-wrap"} and highly statistically significant between the patients and BPH subjects, confirming the same potential biomarker panel found in the training set. The potential biomarker profile database identified in the training set using the SANIST approach was employed to classify the test set. Using this approach, all test set sera with BPH biopsies were matched to training set BPH biopsy samples, while all test set prostate cancer positive patients were matched to training set prostate cancer patients (Table [4](#rcm7270-tbl-0004){ref-type="table-wrap"}). Moreover, a reverse search approach was used by employing the test set as the training set and the training set as the test set; very similar results were obtained, confirming the discriminating power of the SANIST approach. These data indicate that this panel could be a useful tool for supervised diagnostic purposes in prostate cancer due to high reproducibility of the results. A more extensive validation of this panel using a much larger cohort is needed to confirm the clinical usefulness of this panel.

###### 

Ions of the differentially expressed metabolites discovered in the training set in serum samples from an independent set of BPH and PCa positive subjects

  *m/z* value    Ion species           Metabolite name          Fold (Patient area/Control area)   *p* value
  ------------- ------------- --------------------------------- ---------------------------------- -----------
  316.256        \[M+H\]^+^         Decanoyl‐L‐carnitine        0.56                               0.0021
  288.217        \[M+H\]^+^         Octanoyl‐L‐carnitine        0.47                               0.0024
  370.295        \[M+H\]^+^    5‐*cis*‐Tetradecenoyl carnitine  0.41                               0.0075

###### 

Classification percent identity score and absolute identity score, obtained by comparing the second sample set data to the training set using the SANIST platform. All the second samples set (01 suffix) match corresponding training set samples within the respective benign prostate hyperplasia (BPH) and prostate cancer patient (PCa positive) groups. No samples were misclassified

  Sample    SANIST sample classification   Absolute identity (‰)   Percent identity score (%)
  -------- ------------------------------ ----------------------- ----------------------------
  P101              PCa Positive                    804                        90
  P201              PCa Positive                    811                        89
  P301              PCa Positive                    807                        85
  P401              PCa Positive                    815                        91
  P501              PCa Positive                    824                        86
  P601              PCa Positive                    800                        87
  P701              PCa Positive                    781                        87
  P801              PCa Positive                    815                        85
  P901              PCa Positive                    831                        84
  P1001             PCa Positive                    829                        83
  P1101             PCa Positive                    825                        89
  P1201             PCa Positive                    915                        91
  P1301             PCa Positive                    905                        84
  P1401             PCa Positive                    905                        87
  P1501             PCa Positive                    913                        88
  C101                Negative                      909                        88
  C201                  BPH                         907                        81
  C301                  BPH                         907                        86
  C401                  BPH                         911                        85
  C501                  BPH                         913                        84
  C601                  BPH                         912                        84
  C701                  BPH                         917                        86
  C801                  BPH                         918                        86
  C901                  BPH                         914                        83
  C1001                 BPH                         914                        82
  C1101                 BPH                         918                        82
  C1201                 BPH                         917                        83
  C1301                 BPH                         914                        91
  C1401                 BPH                         908                        87
  C1501                 BPH                         908                        89

Conclusions {#rcm7270-sec-0015}
===========

In conclusion, the SANIST bioinformatic application is a dedicated SACI/ESI tool that can identify and analyze biomarker panels.
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Click here for additional data file.
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